Literature DB >> 29248267

A combined carrier-adjuvant system of peptide nanofibers and toll-like receptor agonists potentiates robust CD8+ T cell responses.

Jai S Rudra1, Brianne N Banasik2, Gregg N Milligan3.   

Abstract

Improving CD8+ T cell responses activated by subunit vaccination is crucial for improving vaccine efficacy and safety. Here we report a carrier-adjuvant system composed of self-assembling peptide nanofibers presenting an immunodominant antigen from herpes simplex virus (HSV) and toll-like receptor (TLR) agonists that induces robust effector and memory CD8+ T cell responses in mice. The effector function of vaccine-induced CD8+ T cells was influenced by the type of TLR agonist. The use of CpG (TLR9 agonist) resulted in significantly greater specific in vivo cytotoxicity and trended towards more cells producing both IFN-γ and TNF-α compared to gardiquimod (TLR7 agonist). Prime-boost immunization with peptide nanofibers combined with either adjuvant resulted in development of HSV-specific CD8+ memory T cells further demonstrating the capability of the carrier-adjuvant system to induce strong HSV-specific CD8+ T cell responses. Inclusion of peptide epitope-nanofibers in protein-based subunit vaccines should increase the functional spectrum of the vaccine-elicited immune response and protection.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD8+ T cell; HSV-2; Peptide nanofiber; TLR agonist adjuvants; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 29248267      PMCID: PMC5769694          DOI: 10.1016/j.vaccine.2017.12.017

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Modulating adaptive immune responses to peptide self-assemblies.

Authors:  Jai S Rudra; Tao Sun; Katelyn C Bird; Melvin D Daniels; Joshua Z Gasiorowski; Anita S Chong; Joel H Collier
Journal:  ACS Nano       Date:  2012-01-30       Impact factor: 15.881

2.  Antigenic peptide nanofibers elicit adjuvant-free CD8⁺ T cell responses.

Authors:  Charles B Chesson; Erica J Huelsmann; Andrew T Lacek; Frederick J Kohlhapp; Matthew F Webb; Arman Nabatiyan; Andrew Zloza; Jai S Rudra
Journal:  Vaccine       Date:  2013-12-02       Impact factor: 3.641

3.  Modification of primary and recurrent genital herpes in guinea pigs by passive immunization.

Authors:  Nigel Bourne; Richard B Pyles; David I Bernstein; Lawrence R Stanberry
Journal:  J Gen Virol       Date:  2002-11       Impact factor: 3.891

4.  Immunity to vaginal herpes simplex virus-2 infection in B-cell knockout mice.

Authors:  M B Parr; E L Parr
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

5.  In vivo protective effect of tumour necrosis factor alpha against experimental infection with herpes simplex virus type 1.

Authors:  R Rossol-Voth; S Rossol; K H Schütt; S Corridori; W de Cian; D Falke
Journal:  J Gen Virol       Date:  1991-01       Impact factor: 3.891

6.  Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope.

Authors:  Jai S Rudra; Satish Mishra; Anita S Chong; Robert A Mitchell; Elizabeth H Nardin; Victor Nussenzweig; Joel H Collier
Journal:  Biomaterials       Date:  2012-06-12       Impact factor: 12.479

7.  Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells.

Authors:  H F Staats; J E Oakes; R N Lausch
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

8.  T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2.

Authors:  G N Milligan; D I Bernstein; N Bourne
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

9.  Virus-specific immune memory at peripheral sites of herpes simplex virus type 2 (HSV-2) infection in guinea pigs.

Authors:  Jingya Xia; Ronald L Veselenak; Summer R Gorder; Nigel Bourne; Gregg N Milligan
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

10.  First estimates of the global and regional incidence of neonatal herpes infection.

Authors:  Katharine J Looker; Amalia S Magaret; Margaret T May; Katherine M E Turner; Peter Vickerman; Lori M Newman; Sami L Gottlieb
Journal:  Lancet Glob Health       Date:  2017-01-31       Impact factor: 26.763

View more
  8 in total

Review 1.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

2.  Influences of nanocarrier morphology on therapeutic immunomodulation.

Authors:  Molly Frey; Sharan Bobbala; Nicholas Karabin; Evan Scott
Journal:  Nanomedicine (Lond)       Date:  2018-08-07       Impact factor: 5.307

3.  Alum as an adjuvant for nanoparticle based vaccines: A case study with a hybrid nanoparticle-based nicotine vaccine.

Authors:  Yun Hu; Daniel Smith; Zongmin Zhao; Theresa Harmon; Paul R Pentel; Marion Ehrich; Chenming Zhang
Journal:  Nanomedicine       Date:  2019-06-10       Impact factor: 5.307

4.  Investigating the effects of N-terminal acetylation on KFE8 self-assembly with 2D IR spectroscopy.

Authors:  William B Weeks; Craig J Tainter; Lauren E Buchanan
Journal:  Biophys J       Date:  2022-03-03       Impact factor: 3.699

5.  Enabling sublingual peptide immunization with molecular self-assemblies.

Authors:  Sean H Kelly; Yaoying Wu; Ajay K Varadhan; Elizabeth J Curvino; Anita S Chong; Joel H Collier
Journal:  Biomaterials       Date:  2020-02-24       Impact factor: 12.479

6.  Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity.

Authors:  Rosmely Hernandez; Kevin H Toomer; Janika Põder; Alicia Santos Savio; Sunnie Hsiung; Thomas R Malek
Journal:  Cancer Immunol Immunother       Date:  2020-10-10       Impact factor: 6.968

7.  Nanoscale Peptide Self-assemblies Boost BCG-primed Cellular Immunity Against Mycobacterium tuberculosis.

Authors:  Charles B Chesson; Matthew Huante; Rebecca J Nusbaum; Aida G Walker; Tara M Clover; Jagannath Chinnaswamy; Janice J Endsley; Jai S Rudra
Journal:  Sci Rep       Date:  2018-08-21       Impact factor: 4.379

8.  Development and immunobiological evaluation of nanoparticles containing an immunodominant epitope of herpes simplex virus.

Authors:  Gabriel M Hilario; Fernando B Sulczewski; Raquel Liszbinski; Larissa D Mello; Gustavo Hagen; Tiago Fazolo; Jayme Neto; Eliane Dallegrave; Pedro Romão; Tanira Aguirre; Luiz C Rodrigues Junior
Journal:  IET Nanobiotechnol       Date:  2021-03-30       Impact factor: 2.050

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.